Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics Inc (NQ: MCRB )

1.100 UNCHANGED
Streaming Delayed Price Updated: 12:37 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,303,764
Open 1.100
Bid (Size) 1.090 (27)
Ask (Size) 1.100 (27)
Prev. Close 1.100
Today's Range 1.090 - 1.130
52wk Range 0.5400 - 2.845
Shares Outstanding 127,901,391
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q2 2024
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire

Performance

YTD
-21.43%
-21.43%
1 Month
+15.94%
+15.94%
3 Month
+54.84%
+54.84%
6 Month
+36.41%
+36.41%
1 Year
-60.00%
-60.00%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Seres Therapeutics's Earnings: A Preview
Via Benzinga
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Nasdaq Down Over 50 Points; Uber Posts Q1 Loss
Via Benzinga
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Gold Price Alert: Gold Spot Prices Just Hit a Record High Today
Via InvestorPlace
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For March 5, 2024
Via Benzinga
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
From Seres Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.